Pfizer (NYSE:PFE) Shares Down 1.7% – Time to Sell?

Shares of Pfizer Inc. (NYSE:PFE) were down 1.7% during mid-day trading on Monday . The company traded as low as $27.81 and last traded at $27.8470. Approximately 25,080,212 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 45,450,879 shares. The stock had previously closed at $28.32.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Morgan Stanley set a $27.00 price target on Pfizer and gave the stock a “positive” rating in a research report on Tuesday, March 17th. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. UBS Group initiated coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price for the company. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Finally, Royal Bank Of Canada initiated coverage on shares of Pfizer in a research note on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.19.

Pfizer Stock Down 1.7%

The firm has a fifty day simple moving average of $27.09 and a 200-day simple moving average of $25.84. The company has a market capitalization of $158.35 billion, a PE ratio of 20.48 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Horizon Financial Services LLC increased its holdings in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the fourth quarter worth $26,000. YANKCOM Partnership acquired a new position in Pfizer in the fourth quarter worth $28,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Grey Fox Wealth Advisors LLC acquired a new stake in shares of Pfizer during the third quarter worth $29,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.